To briefly discuss the changing epidemiology of fungal infections and review currently available agents; provide a review of caspofungin; and discuss its pharmacology, pharmacokinetics, dosing guidelines, safety and efficacy, and role in the treatment of invasive fungal infections as it relates to current antifungal therapy.
DATA SOURCES
A MEDLINE (1966 to August 2002) database search using key words caspofungin, echino candins, fungal infections, and invasive aspergillosis, was completed to identify relevant articles including reviews, recent studies, treatment guidelines, and data from Merck and Company.
STUDY SELECTION
In vitro studies and all clinical trials were evaluated to summarize the clinical efficacy and safety of caspofungin.
DATA SYNTHESIS
The incidence of fungal infections is increasing as the population at risk expands. Cost, resistance, and morbidity and mortality are key issues. Adding to the antifungal armamentarium is necessary to address these therapeutic dilemmas. Caspofungin is the first member of a new class of antifungal agents, the echinocandins, to be approved for clinical use. Caspofungin is classified as a glucan synthase inhibitor and represents a class of agents with a novel mechanism of action. Unlike currently available agents (polyenes, pyrimidines, azoles) that exert their effect on the fungal cell membrane, the echinocandins are the first agents to inhibit fungal cell wall synthesis. Caspofungin exhibits activity against Aspergillus spp. and Candida spp., including non-albicans species. Data from clinical trials demonstrate that caspofungin is effective in patients with invasive aspergillosis as well as candida esophagitis. Its Food and Drug Administration–approved indication is limited to invasive aspergillosis refractory to or intolerant of current therapy.
CONCLUSIONS
Caspofungin has activity against Aspergillus spp. as well as a variety of Candida spp. Clinical data support its usefulness in the treatment of invasive aspergillosis and select candida infections. As additional clinical data become available, it seems likely that the therapeutic role of caspofungin will expand.
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT ACPE UNIVERSAL PROGRAM NUMBER: 407-000-03-001-H01
. WeySB, MoriM, PfallerMA, WoolsonRF, WenzelRP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med1988; 148: 2642–5.
4.
. RentzAM, HalpernMT, BowdenR.The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis1998; 27: 781–8.
5.
. KontoyiannisD P, BodeyG P. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis2002; 21: 161–72.
6.
. EdmondMB, WallaceSE, McClishDK, PfallerMA, JonesRN, WenzelR P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis1999; 29: 239–44.
7.
. LewisRE, KlepserME. The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. Am J Health Syst Pharm1999; 56: 525–36.
8.
. PfallerMA, MesserSA, HollisRJ, JonesRN, DoernGV, BrandtME, et al. Trends in distribution and susceptibility to fluconazole among bloodstream isolates of Candida species in the United States. Diag Microbiol Infect Dis1999; 33: 217–22.
9.
. KaoAS, BrandtME, PruittWR, ConnLA, PerkinsBA, StephensDS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis1999; 29: 1164–70.
10.
. PfallerMA, JonesRN, DoernGV, SaderHS, MesserSA, HoustonA, et al. Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother2000; 44: 747–51.
11.
. Rangel-FraustoMS, WiblinT, BlumbergHM, SaimanL, PattersonJ, Ri-naldiM, et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in severe surgical intensive care units and six neonatal intensive care units. Clin Infect Dis1999; 29: 253–8.
. WaldA, LeisenringW, van BurikJ, BowdenRA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis1997; 175: 1459–66.
. PatelR.Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc1998; 73: 1205–25.
16.
. WalshTJ, GoodmanJL, PappasP, BekerskyI, BuellDN, RodenM, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother2001; 45: 3487–96.
17.
. AnaissieEJ, WhiteMH, UzunO et al. Amphotericin B lipid complex vs. amphotericin B for the treatment of invasive candidiasis: a prospective, randomized multicenter trial (abstract LM21). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995: 330.
18.
. Wong-BeringerA, JacobsRA, GugielmoBJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis1998; 27: 603–18.
19.
. OddsFC. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole among pathogenic fungi in vitro. Antimicrob Agents Chemother1982; 22: 763–70.
20.
. OhannoumMA, IbrahimAS,MorataraLA, ShafiqMC, EdwardsJE, CriddleRS. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother1995; 39: 2459–65.
21.
. PolakA.Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis, and wangeillosis in mice. Chemotherapy1987; 33: 381–95.
22.
. BennettJT, DismukesWE, DumaRJ, MedoffG, SandeMA, GallisH, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med1979; 301: 126–31.
23.
. TerrellCL. Antifungal agents. Part II. The azoles. Mayo Clinic Proc1999; 74: 78–100.
24.
. SheehanDJ, HitchcockCA, SibleyCM. Current and emerging azole antifungal agents. Clin Microbiol Rev1999; 12: 40–79.
. BowmanJC, AbruzzoGK, AndersonJW, FlatteryAM, GillCJ, Pikou-nisVB, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: determination of efficacy of caspofungin acetate. Antimicrob Agents Chemother2001; 45: 3471–81.
30.
. Espinel-IngroffA.A comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY 303366 against opportunistic and filamentous and dimorphic fungi and yeasts. J Clin Microbiol1998; 36: 2950–6.
31.
. BartizalK, GillCJ, AbruzzoGK, FlatteryAM, KongL, ScottPM, et al. In vitro preclinical evaluation studies with the echino-candin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother1997; 41: 2326–32.
32.
. DelPoetaM, SchellWA, PerfectJR. In vitro antifungal activity of pneu-mocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother1997; 41: 1835–6.
33.
. BalaniSK, XuX, ArisonBH, SilvaMV, GriesA, DeLunaFA, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos2000; 28: 1274–8.
34.
. DenningDW, LeeJ Y, HostetlerJS, PappasP, KauffmanCA, DewsnupDH, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med1994; 97: 135–44.
35.
. VillaneuvaA, ArathoonEG, GotuzzoE, BermanRS, DiNubileMJ, SableCA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis2001; 33: 1529–35.
36.
. StevensDA, KanVL, JudsonMA, MorrisonVA, DummerS, DenningDW, et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis2000; 30: 696–709.
37.
. EllisM, SpenceD, de PauwB, MeunierF, MarinusA, ColletteL, et al. An EORTC international multicenter randomized trial (EORTC Number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis1998; 27: 1406–12.
38.
. DenningDW, HansonLH, PerlmanAM, StevensDA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis1992; 15: 21–34.
39.
. SchaffnerA, BohlerA.Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses1993; 36: 421–4.
40.
. DenningDW, StevensDA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis1990; 12: 1147–201.
41.
. PoppAI, WhiteMH, QuadriT, WalsheL, ArmstrongD.Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis1999; 3: 157–60.
42.
. SaboJA, Adbel-RahmanSM. Voriconazole: a new triazole antifungal. Ann Pharmacother2000; 34: 1032–43.
43.
. NguyenMH, YuCY. Voriconazole against fluconazole-susceptible and resistant Candida isolates: in vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother1998; 42: 253–6.
44.
. RexJH, WalshTJ, SobelJD, FillerSG, PappasPG, DismukesWE, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis2000; 30: 662–78.
45.
. EdwardsJE, BodeyGP, BowdenRA, BuchnerT, DePauwBE, FillerSG, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis1997; 25: 43–59.
46.
. RexJH, BennettJE, SugarAM, PappasPG, van der HorstCM, EdwardsJE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med1994; 331: 1325–30.
47.
. HughesWT, ArmstrongD, BodeyGP, BowEJ, BrownAE, CalandraT, et al. Guidelines from the Infectious Diseases Society of America: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis2002; 34: 730–51.
48.
. BoogaertsM, WinstonDJ, BowEJ, GarberG, ReboliAC, SchwarerAP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum an tibacterial therapy: a randomized, controlled trial. Ann Intern Med2001; 135: 412–22.
49.
. WalshTJ, PappasP, WinstonDJ, LazarusHM, PetersenF, RafalliJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med2002; 346: 225–34.
50.
. BatesDW, SuL, YuDT, CherkowGM, SegerDL, GomesDR, et al. Mortality and costs of acute renal failure associated with amphotericin-B therapy. Clin Infect Dis2001; 32: 686–93.
51.
. CardinaleV, ed. 2002 Drug topics red book. Montvale, NJ: Medical Economics, 2002.
